Strasbourg, France, March 26, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotechnology firm dedicated to the design and development of virus-based immunotherapies for cancer treatment, has announced its intention to deliver a 30-minute oral presentation on TG4050, the Company’s Individualized Neoantigen Therapeutic Vaccine (INTV), at the upcoming World Vaccine Congress.
The presentation aims to share the positive outcomes associated with TG4050, thus contributing to the scientific discourse surrounding innovative cancer treatment options. This opportunity reflects Transgene’s commitment to advancing research in the field of immunotherapy and its potential to address the unique challenges posed by cancer.
For those interested in developments in immunotherapy and related funding opportunities, further information can be found through relevant channels.